What's in Viking Therapeutics, Inc.'s pipeline?

Viking Therapeutics, Inc. has 4 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 2 in Phase 1.

Which companies overlap with Viking Therapeutics, Inc.'s portfolio?

Top competitors by shared drug class: HK inno.N Corporation.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/viking-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Viking Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Viking Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
VK2735	VK2735	phase 3	Dual GLP-1/GCG receptor agonist	GLP-1R, GCGR	Endocrinology, Obesity, Diabetes

Therapeutic area mix

Endocrinology, Obesity, Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

HK inno.N Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Viking Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Viking Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/viking-therapeutics-inc. Accessed 2026-05-16.